Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

INDUSTRY 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 2Melanoma 2Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × talabostat × Clear all
NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00080080 2007-06-08

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Point Therapeutics

Phase 2 Completed
Thoracic

Lung Neoplasms

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡